Physician profile
Mark Pizzurro
NPI 1952505398
$239,055.96
in general payments reported to CMS, 2019-2025
12 companies · $38K in 2025
The $38K reported for 2025 was more than what 86% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $43K · 2021: $40K · 2022: $40K · 2023: $29K · 2024: $27K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $85K · Travel and Lodging: $4,788 · Food and Beverage: $3,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $85,401.00 |
| Travel and Lodging | $4,787.92 |
| Food and Beverage | $3,160.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $237,708.09 | 2019-2025 | Mako, Insignia, Aequalis |
| Seapearl East, INC | $645.15 | 2023 | |
| Depuy Synthes Sales INC. | $188.73 | 2023-2025 | Monovisc |
| Davol INC. | $161.57 | 2022-2025 | Surgiphor |
| Sanara Medtech INC. | $124.80 | 2024 | Celleraterx |
| Kerecis Limited | $56.37 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Becton, Dickinson and Company | $44.51 | 2024 | Channel Drain |
| Solventum Corporation | $39.83 | 2025 | Prevena |
| Integra Lifesciences Corporation | $26.21 | 2019 | |
| Axogen | $24.97 | 2019 | |
| Smith+Nephew, INC. | $21.63 | 2025 | Pico 14 |
| Bioventus LLC | $14.10 | 2024 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pizzurro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.